Theravance Biopharma Stock Price, News & Analysis (NASDAQ:TBPH)

$28.54 -0.04 (-0.14 %)
(As of 11/22/2017 07:26 AM ET)
Previous Close$28.58
Today's Range$28.11 - $28.79
52-Week Range$23.15 - $43.44
Volume247,000 shs
Average Volume237,604 shs
Market Capitalization$1.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.41

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:TBPH
  • Previous Symbol: NASDAQ:TBPHV
  • CUSIP: N/A
  • Web: www.theravance.com
Debt:
  • Debt-to-Equity Ratio: 1.21%
  • Current Ratio: 7.53%
  • Quick Ratio: 7.21%
Sales & Book Value:
  • Annual Sales: $48.65 million
  • Price / Sales: 31.74
  • Book Value: $3.40 per share
  • Price / Book: 8.39
Profitability:
  • Trailing EPS: ($5.16)
  • Net Income: $-190,660,000.00
  • Net Margins: -1,604.87%
  • Return on Equity: -99.43%
  • Return on Assets: -47.10%
Misc:
  • Employees: 316
  • Outstanding Shares: 54,100,000
 

Frequently Asked Questions for Theravance Biopharma (NASDAQ:TBPH)

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.01. The biopharmaceutical company earned $5.47 million during the quarter, compared to the consensus estimate of $6.19 million. Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%. View Theravance Biopharma's Earnings History.

Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?

6 Wall Street analysts have issued twelve-month price targets for Theravance Biopharma's shares. Their predictions range from $22.00 to $55.00. On average, they expect Theravance Biopharma's stock price to reach $42.67 in the next year. View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) Revefenacin NDA filing anticipated in 4Q17, potential regulatory approval in the U.S. for COPD in ’18, Phase 3b PIFR study, designed to support commercialization, expected to complete in 1Q18.; 2) Trelegy Ellipta, commercial launch expected mid-November ’17, economic interest related to Trelegy Ellipta entitles TBPH to upward tiering royalty of 5.5-8.5% on worldwide net sales; potential regulatory approval in the EU for COPD in late ’17, Phase 3 CAPTAIN study in asthma patients expected to complete in ’18; 3) TD-1473 data from the remaining cohorts of the Phase 1b study in patients with ulcerative colitis in ’18, targeting initiation of large, multi-dose induction and maintenance study in ’18; 4) TD-9855, data from the Phase 2a study in patients with nOH in 1H18; 5) Vibativ, Observational Use Registry (TOUR) data to be published in ’18, data from the Phase 3 registrational bacteremia study in ’18 or ’19; and, 4) Cash and equivalents totaled $434.4MM as of 9/30/17." (11/7/2017)
  • 2. According to Zacks Investment Research, "Theravance has only one marketed product in its portfolio, Vibativ. Though Vibativ continues to perform well, the company’s sole dependence on the drug for growth is concerning. Moreover, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. However, we are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Its shares have outperformed the industry so far this year." (10/10/2017)
  • 3. Needham & Company LLC analysts commented, "Theravance reported top-line results from Phase 2b trial of velusetrag in Gastroparesis. Statistically significant and dose-dependent improvements in gastric emptying were observed across all 3 doses tested. Symptomatic benefits, however, were only observed at lowest dose. Mgmt speculated that excessive gastric emptying into small intestine may have led to a separate set of symptoms negating any benefits. Explanation appears plausible, but we await details at future medical mtg. Regardless, efficacy in 5mg arm is sufficiently strong to justify Phase 3 development, considering both key pre-specified endpoints were met at 4wks (Gastroparesis Cardinal Symptom Index p=0.033 and Gastroparesis Rating Scale p=0.016), w/ all 10 subscales favoring drug over placebo. Effects were observed in both Diabetic and Idiopathic pts and persisted through 12wks. Mgmt plans to meet w/ FDA to discuss Phase 3 design." (8/2/2017)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:

  • Rick E. Winningham, Chairman of the Board, Chief Executive Officer (Age 57)
  • Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer (Age 45)
  • Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 57)
  • Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer (Age 47)
  • Sharathchandra S. Hegde, Senior Vice President, Research (Age 53)
  • Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer (Age 61)
  • Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning (Age 53)
  • Shehnaaz Suliman M.D., Senior Vice President - Corporate Development and Strategy
  • Philip D. Worboys Ph.D., Senior Vice President, Translational Science (Age 47)
  • William D. Young, Lead Independent Director (Age 72)

Who owns Theravance Biopharma stock?

Theravance Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (3.00%), Bank of New York Mellon Corp (0.39%), Schwab Charles Investment Management Inc. (0.35%), Wells Fargo & Company MN (0.22%), Old West Investment Management LLC (0.21%) and California Public Employees Retirement System (0.14%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Frank Pasqualone, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?

Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Manhattan Co., NJ State Employees Deferred Compensation Plan, California Public Employees Retirement System, Candriam Luxembourg S.C.A., California State Teachers Retirement System, Old West Investment Management LLC and Principal Financial Group Inc.. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer and Brett K Haumann. View Insider Buying and Selling for Theravance Biopharma.

Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?

Theravance Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Schwab Charles Investment Management Inc., Moneta Group Investment Advisors LLC, First Trust Advisors LP, Alps Advisors Inc., SG Americas Securities LLC, Bank of New York Mellon Corp and Legal & General Group Plc. Company insiders that have bought Theravance Biopharma stock in the last two years include Frank Pasqualone, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

How do I buy Theravance Biopharma stock?

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of Theravance Biopharma stock can currently be purchased for approximately $28.54.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.54 billion and generates $48.65 million in revenue each year. The biopharmaceutical company earns $-190,660,000.00 in net income (profit) each year or ($5.16) on an earnings per share basis. Theravance Biopharma employs 316 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, KY1-1104, Cayman Islands. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Theravance Biopharma (NASDAQ:TBPH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $42.67 (49.50% upside)

Consensus Price Target History for Theravance Biopharma (NASDAQ:TBPH)

Price Target History for Theravance Biopharma (NASDAQ:TBPH)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Cantor FitzgeraldReiterated RatingBuy$55.00N/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$45.00MediumView Rating Details
8/2/2017Needham & Company LLCReiterated RatingBuyHighView Rating Details
5/10/2017Leerink SwannSet Price TargetBuy$47.00LowView Rating Details
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00MediumView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/3/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Theravance Biopharma (NASDAQ:TBPH)

Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Earnings History by Quarter for Theravance Biopharma (NASDAQ TBPH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
2017 EPS Consensus Estimate: ($4.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.04)($1.04)($1.04)
Q2 20171($1.07)($1.07)($1.07)
Q3 20171($1.26)($1.26)($1.26)
Q4 20171($1.16)($1.16)($1.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Theravance Biopharma (NASDAQ TBPH)

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 83.84%
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Insider Trades by Quarter for Theravance Biopharma (NASDAQ TBPH)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Bradford J ShaferEVPSell14,670$30.77$451,395.90View SEC Filing  
8/21/2017Frank PasqualoneSVPBuy4,000$26.34$105,360.00View SEC Filing  
8/11/2017Henrietta ForeDirectorBuy6,000$23.99$143,940.00View SEC Filing  
8/11/2017Rick E WinninghamCEOBuy10,000$24.50$245,000.00View SEC Filing  
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Theravance Biopharma (NASDAQ TBPH)

Source:
DateHeadline
Theravance Biopharma to Present at Two Upcoming Investor ConferencesTheravance Biopharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 21 at 11:32 AM
Theravance Biopharma to Present at Two Upcoming Investor ConferencesTheravance Biopharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 21 at 11:32 AM
Theravance Biopharma (TBPH) Reports European Marketing Authorization for ...Theravance Biopharma (TBPH) Reports European Marketing Authorization for ...
www.streetinsider.com - November 18 at 9:11 AM
3 Things In Biotech You Should Learn Today: November 14, 20173 Things In Biotech You Should Learn Today: November 14, 2017
seekingalpha.com - November 15 at 1:59 PM
$3.72 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter$3.72 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - November 14 at 6:04 AM
-$1.15 EPS Expected for Theravance Biopharma, Inc. (TBPH) This Quarter-$1.15 EPS Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - November 12 at 1:24 PM
Theravance Biopharma, Inc. Forecasted to Earn FY2017 Earnings of ($4.95) Per Share (TBPH)Theravance Biopharma, Inc. Forecasted to Earn FY2017 Earnings of ($4.95) Per Share (TBPH)
www.americanbankingnews.com - November 10 at 12:54 PM
Theravance Bio reports 3Q lossTheravance Bio reports 3Q loss
finance.yahoo.com - November 9 at 2:29 PM
Edited Transcript of TBPH earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of TBPH earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 2:29 PM
Theravance Biopharma, Inc. (TBPH) Rating Reiterated by Cantor FitzgeraldTheravance Biopharma, Inc. (TBPH) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 7:48 PM
Head to Head Analysis: Theravance Biopharma (TBPH) vs. Aegerion Pharmaceuticals (AEGR)Head to Head Analysis: Theravance Biopharma (TBPH) vs. Aegerion Pharmaceuticals (AEGR)
www.americanbankingnews.com - November 3 at 11:20 PM
Reviewing Theravance Biopharma (TBPH) and Its CompetitorsReviewing Theravance Biopharma (TBPH) and Its Competitors
www.americanbankingnews.com - November 2 at 7:22 PM
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...
www.prnewswire.com - November 1 at 9:38 AM
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...
www.prnewswire.com - November 1 at 9:38 AM
Theravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient RegistryTheravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient Registry
www.streetinsider.com - November 1 at 9:38 AM
Theravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient RegistryTheravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient Registry
www.streetinsider.com - November 1 at 9:38 AM
Theravance Biopharma Announces Opening of Companys New Corporate Office in Dublin, IrelandTheravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland
finance.yahoo.com - November 1 at 9:38 AM
Theravance Biopharma Announces Opening of Companys New Corporate Office in Dublin, IrelandTheravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland
finance.yahoo.com - November 1 at 9:38 AM
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual MeetingTheravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
finance.yahoo.com - November 1 at 9:38 AM
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual MeetingTheravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
finance.yahoo.com - November 1 at 9:38 AM
Theravance Biopharma, Inc. (TBPH) Given Average Recommendation of "Hold" by AnalystsTheravance Biopharma, Inc. (TBPH) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 1 at 3:32 AM
Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - October 31 at 10:19 AM
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual MeetingTheravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual Meeting
finance.yahoo.com - October 31 at 10:19 AM
Financial Analysis: Theravance Biopharma (TBPH) and The CompetitionFinancial Analysis: Theravance Biopharma (TBPH) and The Competition
www.americanbankingnews.com - October 30 at 1:26 PM
Reviewing Theravance Biopharma (TBPH) and Its PeersReviewing Theravance Biopharma (TBPH) and Its Peers
www.americanbankingnews.com - October 28 at 9:30 AM
Theravance Biopharma Becomes Oversold (TBPH)Theravance Biopharma Becomes Oversold (TBPH)
www.nasdaq.com - October 27 at 9:07 PM
Analyzing Novartis AG (NVS) & Theravance Biopharma (TBPH)Analyzing Novartis AG (NVS) & Theravance Biopharma (TBPH)
www.americanbankingnews.com - October 27 at 10:00 AM
Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : October 26, 2017Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : October 26, 2017
finance.yahoo.com - October 26 at 12:52 PM
$3.60 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter$3.60 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - October 25 at 3:42 PM
Theravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual MeetingTheravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting
finance.yahoo.com - October 25 at 3:22 PM
Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : October 25, 2017Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : October 25, 2017
finance.yahoo.com - October 25 at 3:22 PM
Theravance Biopharma (TBPH) Announces Positive New Data from Multiple Studies of VIBATIV (telavancin)Theravance Biopharma (TBPH) Announces Positive New Data from Multiple Studies of VIBATIV (telavancin)
www.streetinsider.com - October 11 at 8:24 AM
Theravance Biopharma, Inc. (TBPH) Raised to "Hold" at Zacks Investment ResearchTheravance Biopharma, Inc. (TBPH) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 10 at 1:56 PM
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017
finance.yahoo.com - October 10 at 7:20 AM
Theravance Biopharma, Inc. (TBPH) Receives Average Rating of "Hold" from AnalystsTheravance Biopharma, Inc. (TBPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 7 at 4:52 AM
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV ...Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV ...
www.prnewswire.com - October 3 at 1:20 PM
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017
finance.yahoo.com - October 3 at 1:20 PM
Theravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowTheravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 29 at 9:13 AM
Theravance Biopharma, Inc. (TBPH) Earns Buy Rating from Cantor FitzgeraldTheravance Biopharma, Inc. (TBPH) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 27 at 5:32 PM
Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the USTheravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
finance.yahoo.com - September 20 at 9:49 AM
Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare ConferenceTheravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 9:49 AM
Cantor Fitzgerald Reiterates "Buy" Rating for Theravance Biopharma, Inc. (TBPH)Cantor Fitzgerald Reiterates "Buy" Rating for Theravance Biopharma, Inc. (TBPH)
www.americanbankingnews.com - September 19 at 3:16 PM
Theravance Biopharma Highlights GlaxoSmithKline and Innovivas Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)
finance.yahoo.com - September 19 at 8:18 AM
-$1.26 Earnings Per Share Expected for Theravance Biopharma, Inc. (TBPH) This Quarter-$1.26 Earnings Per Share Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - September 16 at 2:28 AM
ETFs with exposure to Theravance Biopharma, Inc. : September 14, 2017ETFs with exposure to Theravance Biopharma, Inc. : September 14, 2017
finance.yahoo.com - September 14 at 11:03 AM
Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : September 14, 2017Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : September 14, 2017
finance.yahoo.com - September 14 at 11:03 AM
Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 12 at 10:38 AM
Theravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of "Hold" from AnalystsTheravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 12 at 4:40 AM
Bradford J. Shafer Sells 14,670 Shares of Theravance Biopharma, Inc. (TBPH) StockBradford J. Shafer Sells 14,670 Shares of Theravance Biopharma, Inc. (TBPH) Stock
www.americanbankingnews.com - September 8 at 7:52 PM
Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare ConferenceTheravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 9:01 AM

Social Media

Financials

Chart

Theravance Biopharma (NASDAQ TBPH) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.